spot it early

Early Cancer Detection is One Breath Away

July, 2026



*SpotitEarly tests are not intended to replace current screening procedures, but rather to be used as an additional pre-screening layer to complement preventative protocols already in place.

*The SpotitEarly tests have not been approved by the Food and Drug Administration (FDA) and are currently under development and validation.

SpotitEarly's Vision

A world where cancer is caught in time.
for everyone.

TODAY CANCER SCREENING IS A

BURDEN

Less than

50%

Stay on their Screening Schedule

- Invasive and unpleasant
- A separate test for each cancer type
- Radiation exposure (Mammogram, CT)
- Expensive
- Only moderately accurate

Cancer screening as easy as breathing

- At-home, easy to use collection kit
- Four cancers in one test
  breast, lung, colorectal, prostate
- Highly accurate at early stages

So people actually keep screening



Just breathe for **3min**

Volatile Organic Compounds (VOCs)

Metabolic Fingerprints of Disease

Chemicals released by cells across the body.

- Present in breath, blood, and urine
- Breath enables non-invasive sampling
- **Cancer cells** emit unique **VOC signatures**

Exhaled in breath - a promising diagnostic medium.

Dogs are **clinically proven** bio-detectors

Multiple studies have shown that dogs can accurately identify the scent of of cancer, earlier than medical diagnostics devices

Study	Sensitivity	Specificity	Malignancy
McCulloch et al. (2006)	99%	99%	Lung Cancer
	88%	98%	Breast Cancer
Hideto Sonoda et al. (2011)	99%	91%	Colorectal cancer
Cornu et al. (2011)	91%	91%	Prostate Cancer
Buszewski et al. (2012)	82%	82%	Lung Cancer
Horvath et al. (2013)	97%	99%	Ovarian cancer
Rudnicka et al. (2014)	86%	72%	Lung Cancer
Ehmann et al. (2014)	71%	93%	Lung Cancer
Guerrero-Flores et al. (2017)	90%	90%	Cervical Cancer
Charlotte Feil et al. (2021)	97.6%	Not provided	Lung Cancer
Agustin et al. (2022)	100%, 98%	99%, 99%	Osteosarcoma

Inside **the Lab**: LUCID **Bio-AI Hybrid** technology stack

LUCID consists of three integrated layers in one continuously learning system.

Bio-Olfactory Detection

Trained canine bio-detectors

- 300M olfactory receptors per dog
- Detect cancer VOCs at parts-per-trillion

13 trained detection dogs

Multi-Modal Sensor Array

Video, audio, and motion capture

- Captures video, audio & motion cues
- Synced in real time via Lucid Station

Thousands of unique data points

Deep Learning AI Models

Multi-model CNN architecture

- CNN models analyze sensor data in real time
- Outputs a signal detected / not detected call

0-100 confidence per sample

Inside **the Lab**: LUCID **Bio-AI Hybrid** technology stack

Capacity grows by adding rooms, teams, or operating hours.

PEAK ANNUAL CAPACITY

1.73M

samples per year

4 Rooms × 3 Teams

Base scenario, 2 hours/day, 250 working days

6,912
samples / day

384
samples / hour

Modular by design

- Capacity scales linearly with each team or room added
- Adding teams is the lower-capex path to scale

Horizontal + vertical packs

- Horizontal packs: multi-cancer screening at scale
- Vertical packs: single-cancer testing

Operating foundation

- 6 testing rounds per day; 6 stations per room
- 250 working days per year underpin all capacity figures

SpotitEarly: Clinically Proven

Double blind results:

93.87% Sensitivity

245/261

94.27% Specificity

988/1048

* Published in *Scientific Reports* by Nature Group

Sensitivity by cancer type*:



SpotitEarly performs better than liquid biopsies at early stages



Resource 1 Resource 2

Traction

Partnerships:

Penn Medicine

Fox Chase Cancer Center
Temple Health

Hackensack Meridian *Health*

HOSPITAL Assuta RAISING HEALTH STANDARDS

SHEBA Tel HaShomer City of Health

TEL AVIV SOURASKY MEDICAL CENTER ICHILOV

Hadassah Medical Center

RAMBAM Health Care Campus

Signed LOI's:

WIX

SK GROUP

gottex

Regulation:

CLIA

CLIA certified Laboratory

Funding

Grants: $3.6m

Equity: $16.7m

Israel ministry of Health

Israel Innovation Authority

BIRD Foundation

Remarkable VCs

Hanaco VC

Menomedin VC

Ventures VC

Exceptional Angels

Jeff Swartz
Timberland

Avishai Avrahami
WIX

Michael Eisenberg
Aleph VC

Sunny Sassoon
The coffee bean

Mitch Julis
Canyon Partners

Yair Iowenstein
Altshuler Shaham

Roadmap: 2027 to 2032

Growth Path: market entry, scale, and exit

PHASE 1

2027

Market Entry

- CLIA/LDT launch in the U.S. for Breast & Lung breath tests
- Health systems, consumer ordered via physician network

Estimated Revenue **$3.3M**

PHASE 2

2028 to 2031

Scale & Multi-Cancer

- Multi-cancer expansion beyond breast and lung
- Early international pilots (Europe, Asia)
- LUCID platform licensing worldwide ($100M+ yearly potential)

Estimated Revenue by 2031 **$139M**

PHASE 3

2031 to 2032

Market Leadership

- Coverage into Medicare and Medicaid
- Multi-cancer leader; LUCID-as-a-service beyond cancer
- 2.5M to 4M tests/year (10 to 15% MCED market share)

Estimated Revenue **$500M to $1B+**

EXIT OPPORTUNITIES

IPO / Public Listing

NASDAQ listing, timing kept open

Strategic Acquisition

5x to 15x revenue, invested capital for category leaders.

POTENTIAL ACQUIRERS

- Roche
- Quest Diagnostics
- Abbott/Exact Sciences
- Guardant Health
- LabCorp
- Danaher

Competitive landscape



Categories

- SpotitEarly, Bio-AI Hybrid breath
- Multi-cancer test (blood or breath)
- Breast-specific test
- Standard-of-care imaging

*Bubble mark = relative cost, **$** to **$$$**. No mark = pre-commercial.*

Only SpotitEarly pairs performance on par with gold-standard screening with the accessibility of a non-invasive test.

Scientific Advisors

Prof. Raanan Berger

Head, Institute of Oncology, Sheba Medical Center.

Jonathan Fleming

Highly experiences medtech entrepreneur and investor. Senior lecturer at MIT.

Prof. David Sidransky

Professor of Oncology at Johns Hopkins School of Medicine Specializes in biomarkers .

Prof. Eitan Friedman

Director and founder of the The Suzanne Levy-Gertner Oncogenetics Unit at the Sheba Medical Center.

Prof. Vivian Barak

Head of Immunology & Tumor Diagnosis Lab at the Oncology Department of Hadassah Medical Center.

Prof. Yosi Yovel

Head of the lab of NeuroEcology in the School of Zoology and the head of the Sagol School of Neuroscience at Tel Aviv University.

Robbie Evans

Managing Director of Leeds United and ex-Chief Strategy Officer at Invitae which he scaled to a public company with $500M annual revenue.

Leadership

32 employees

8 PhDs

55% 👩

45% 👨

CxOs:

Experienced entrepreneurs with multiple exits and IPOs.

Roi Ophir

Co-founder, Chairman

Shlomi Madar, PhD

CEO

Ariel Ben-Dayan

Co-founder, exec director

Udi Bobrovsky

Co-founder, COO

Ohad Sharon

Co-founder, CSO (Strategy)

Shai Lankry

CFO

Amir Lifshitz

SVP Operations

Yossi Melamed

VP Canine operations

Asaf Ruf

VP R&D

Irit Gazit, PhD

Director of canine applied research

Reef Einoch Amor, PhD

Director of chemical analytics

Veena Singh, MD, FCAP, FACMG

Director of Clinical lab

Hagit Shapira, PhD

Clinical lab general supervisor

Nirit Blayer

Director of QA/RA and Software Compliance

spot it early

Series A funding:

$20M

Valuation: $140M

Discounted share price for $5M+ investments (see POM)

Open for accredited investors under SEC Reg D

Use of proceeds:

US Product **commercialization**

& Initial sales (15K screening kits)

- Commercial launch
- Establish US operations including a US lab
- Ongoing clinical validation
- Deepen our AI & detection platform

spot it early

Thank you!



*SpotitEarly tests are not intended to replace current screening procedures, but rather to be used as an additional pre-screening layer to complement preventative protocols already in place.
*The SpotitEarly tests have not been approved by the Food and Drug Administration (FDA) and are currently under development and validation.